KRYS News and Press, Krystal Biotech Inc. From 12/02/21

Krystal Biotech (NASDAQ: KRYS) saw its shares climb more than 77% this week, according to data provided by S&P Global Market Intelligence . The stock was only at $39.81 at Friday's close, then opened at $91.20 on Monday and climbed to as high as $102.99. While the stock has ...

Shares of the gene therapy specialist Krystal Biotech (NASDAQ: KRYS) are down by 13.6% as of 1:38 p.m ET Wednesday afternoon. The biotech's shares are sinking today in response to a $200 million public offering. More specifically, Krystal announced yesterday that it plans an off...

Krystal Biotech (NASDAQ:KRYS) has priced its public offering of ~2.7M shares of common stock, at $75.00/share, for expected gross proceeds of ~$200M. Underwriters' over-allotment is an additional 400K shares. All of the shares will be sold by the Company other than up to 200K that may be sold...

PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its com...

Positive results were obtained from the phase 3 GEM-3 study using VYJUVEK for the treatment of patients with dystrophic Epidermolysis Bullosa. STAR-D technology platform is highly efficient in using an engineered non-encoding HSV-1 viral vector to deliver a large gene or multiple gene...

Monday saw a substantial rebound following the Omicron-related sell-off that took place going into the weekend. The recovery included the oil sector, with Devon Energy (NYSE:DVN), Diamondback Energy (NASDAQ:FANG), APA Corp. (NASDAQ:APA) and Baker Hughes (NYSE:BKR) all posted gains on the sess...

Krystal Biotech (NASDAQ:KRYS) trades 5.4% higher after hours on commencing a $200M underwritten public offering of its common stock; company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30M of share...

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and ...

Shares of Krystal Biotech Inc ( NASDAQ: KRYS ) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its primary and secondary endpoint According to Krystal Biotech, the study in...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Krystal Biotech (NASDAQ: KRYS ) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial. Source: Bukhta Yurii / Shutterstock.com The clinical trial behind today’...